The number of brain lesions remains the strongest prognostic factor.
Picking the optimal early therapy for an individual with clinically isolated syndrome (CIS) is a major objective in slowing disease progression. However, studies designed to identify which patients are at risk for developing multiple sclerosis (MS) and worsening disability have been limited.
Now, investigators have conducted a large, prospective cohort study of 1015 CIS patients presenting with optic neuritis (37% of patients), brainstem symptoms (27%), transverse myelitis (26%), or other syndromes (11%). Of those who underwent lumbar puncture, 57% had cerebrospinal fluid (CSF) that was positive for oligoclonal bands. Of those who underwent brain magnetic resonance imaging (MRI), 31% had normal findings, 29% had 1 to 9 T2 lesions, and 40% ha…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)